Compare FOA & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FOA | SABS |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | 63 |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 183.8M | 198.5M |
| IPO Year | N/A | N/A |
| Metric | FOA | SABS |
|---|---|---|
| Price | $21.72 | $4.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $29.75 | $9.80 |
| AVG Volume (30 Days) | 81.8K | ★ 465.5K |
| Earning Date | 03-10-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $318,296,000.00 | $114,698.00 |
| Revenue This Year | $29.44 | N/A |
| Revenue Next Year | $14.30 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.58 | $1.00 |
| 52 Week High | $29.58 | $6.60 |
| Indicator | FOA | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 36.88 | 45.22 |
| Support Level | $21.56 | $4.27 |
| Resistance Level | $23.60 | $4.68 |
| Average True Range (ATR) | 0.84 | 0.26 |
| MACD | -0.22 | -0.03 |
| Stochastic Oscillator | 10.91 | 15.12 |
Finance of America Companies Inc is a financial services holding company that, through its operating subsidiaries, is a modern retirement solutions platform that provides customers with access to a range of retirement offerings centered on the home. In addition, FoA offers capital markets and portfolio management capabilities to optimize the distribution of its originated loans to investors. It operates through two segments: Retirement Solutions and Portfolio Management. It generates the majority of its revenue from Retirement Solutions.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.